ROIV News and Press, Roivant Sciences Ltd. From 08/14/23

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses First patient has been dosed in the TAHOE study, a global Phase 2 trial of RVT-3...

2023-08-13 08:02:00 ET More on Cisco, Deere, etc. Compare metrics for CSCO to DE, HD, SNDL, TGT, WMT Walmart: The Bottom Could Fall Out If Inflation Levels Continue To Fall Home Depot: Long-Term Winner, With Room To Run Target estimates lowered at Barclays ah...

2023-08-11 13:08:09 ET Roivant Sciences ( NASDAQ: ROIV ) is scheduled to announce Q1 earnings results on Monday, August 14th, before market open. The consensus EPS Estimate is -$0.27 (+43.7% Y/Y) and the consensus Revenue Estimate is $24.49M (+466.9% Y/Y).Over the last 1 yea...

2023-08-11 09:56:34 ET Major earnings expected before the bell on Monday include: Atossa Therapeutics ( ATOS ) JinkoSolar Holding ( JKS ) Niu Technologies ( NIU ) Sundial Growers ( SNDL ) 22nd Century Group ( XXII ) For further details see: ...

BASEL, Switzerland and LONDON and NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 14, 2023, to report its financial results for the quarter ended June 30, 2023, and provide a ...

BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and,...

2023-07-28 05:31:08 ET Summary Arcutis has launched Zoryve, a topical cream for the treatment of psoriasis, and is focused on transitioning to a commercial-stage company. The company has made progress with major pharmacy benefit managers and positioned Zoryve to be highly accessib...

The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of RVT-3101 in patients with moderate to severely active Crohn’s disease (CD) Roivant recently announced highly favorable results from the TUSCANY-2 Phase 2b study in ulcerative colitis (UC),...

2023-07-19 19:46:00 ET Shares of Immunovant ( NASDAQ: IMVT ) jumped 14% midday Monday amid the release of positive data for Argenx's ( ARGX ) drug Vyvgart Hytrulo, which is in the same drug class as Immunovant's drug candidate IMVT-1402. Argenx reported earlier Monday that a...

2023-07-19 17:50:15 ET Summary Immunovant, Inc. received additional validation with anti-FcRn achieved as competitor argenx achieves primary endpoint in phase 2 study using VYVGART for the treatment of patients with CIDP. Immunovant expects to release results from its phase 2b stu...